Underwriters consider a variety of factors in pricing policies, including the fund's size, its strategy, investor-base, performance, volatility, leverage and service providers.
However, the claims that the defects can be passed on, if proven, would add strength to Thalidomide UK's repeated calls for the size of the fund to be boosted.